CoChat

Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design

Open access
Allen, Alina M., Therneau, Terry M., Ahmed, Omar T., Gidener, Tolga, Mara, Kristin C., Larson, Joseph J., Canning, Rachel E., Benson, Joanne T., Kamath, Patrick S. · 2022 · Journal of Hepatology
Cited by 121

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background and Aims: The predicted risk and timeline to progression to liver outcomes in NAFLD are not well-characterized in the population. We aimed to examine the risk and time to progression to cirrhosis, hepatic decompensation and death in a contemporary population with long follow-up, in order to inform effectiveness endpoints and sample calculations in clinical trials of cirrhosis. Methods: This is a retrospective study of prospectively collected data in a medical record linkage system including all adults diagnosed with NAFLD between 1996-2016 by clinical, biochemical and radiological criteria in Olmsted County, Minnesota and followed until 2019. Liver-related outcomes and death were ascertained and validated by individual medical record review. Time and risk of progression from NAFLD to cirrhosis to decompensation and death were assessed using multistate modeling. Results: A total of 5123 NAFLD individuals (median age 52 years, 53% women) were followed for a median of 6.4 (range 1-23) years. The risk of progression was as follows: from NAFLD to cirrhosis: 3% in 15 years; compensated cirrhosis to first decompensation: 33% in 4 years (8%/year); first decompensation to two or more: 47% in 2 years. Albumin, bilirubin, non-bleeding esophageal varices and diabetes were independent predictors of decompensation. Among the 575 deaths, 6% were liver-related. Therapeutic trials in compensated cirrhosis would require minimum enrollment criteria of 2,886 subjects followed over 2 years to detect at least 15% relative decrease in liver endpoints. Conclusion: In this population-based cohort with 23 years of longitudinal follow-up, NAFLD was slowly progressive, with liver-related outcomes affecting only a small proportion of people. Reduction in liver related endpoints in clinical trials require large sample sizes and long follow-up.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2022.07.004

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 121

Metadata

Authors
Allen, A. M., Therneau, T. M., Ahmed, O. T., Gidener, T., Mara, K. C., Larson, J. J., Canning, R. E., Benson, J. T., & Kamath, P. S.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2022-11
Volume
77
Issue
5
Pages
1237-1245
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4285678391
Cited by
121
References
7
FWCI
16.23
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. https://app.cochat.ai/papers/10.1016/j.jhep.2022.07.004
The paper
Allen, A. M., Therneau, T. M., Ahmed, O. T., Gidener, T., Mara, K. C., Larson, J. J., Canning, R. E., Benson, J. T., & Kamath, P. S. (2022). Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2022.07.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.